<![CDATA[Autism spectrum disorder requires accessible and objective neurophysiological biomarkers to complement behavioral assessment, particularly for early screening in resource-limited settings. This study explores a computationally efficient framework for distinguishing children with autism spectrum disorder from neurotypical controls using beta-band electroencephalography activity (12–30 Hz), which has been associated with atypical sensorimotor and cognitive processing in autism. Beta-band oscillations are theoretically relevant for their roles in attention, cognitive control, and inhibitory processes, domains frequently disrupted in autism spectrum disorder. Data were obtained from the public King Abdulaziz University dataset comprising 16 male participants (8 with autism, 8 controls; aged 6–14 years). Following independent component analysis-based artifact removal and bandpass filtering, recordings were segmented into 2-s epochs with 50% overlap. Discrete wavelet transform (Daubechies-4, four levels) was applied to extract statistical features (mean, standard deviation, skewness, kurtosis) from wavelet coefficients across 16 EEG channels, yielding a 320-dimensional feature vector per epoch. Classification was performed using least-squares support vector machines with a polynomial kernel (degree d=3), with hyperparameters optimized via 5-fold cross-validation on the training set, and evaluated via a stratified 70/30 train–test split at the segment level. The polynomial-kernel model achieved 98.49% segment-level accuracy, outperforming the linear kernel (95.07%) and a relative beta-power baseline. However, these results should be interpreted with caution due to the small sample size (n=16), a male-only cohort, and segment-level evaluation, which may inflate performance through intra-subject data leakage. The lightweight computational design supports potential implementation on portable devices. This proof-of-concept demonstrates the feasibility of wavelet-based beta-band analysis for autism classification, but rigorous validation using larger, balanced cohorts with subject-wise cross-validation is essential before clinical translation can be considered.]]>
